Literature DB >> 2965643

Soluble CD23 is released by B lymphocytes cycling in response to interleukin 4 and anti-Bp50 (CDw40).

J Cairns1, L Flores-Romo, M J Millsum, G R Guy, S Gillis, J A Ledbetter, J Gordon.   

Abstract

An enzyme-linked immunoassay was developed to quantitate the production of soluble CD23 from cycling B lymphocytes. This molecule has identity both with B cell-derived B cell growth factor and with an IgE-binding factor. B lymphocytes, which had been stimulated for 3 days with phorbol dibutyrate and calcium ionophore, washed and recultured, failed to produce detectable levels of CD23 over the following 3 days. Soluble CD23 was found, however, in the supernatant of cultures where recombinant interleukin 4 had been included. The level of CD23 rose dramatically when anti-Bp50 had also been added. By contrast, anti-Bp50, alone or together with low molecular weight T cell-derived B cell growth factor, failed to promote the release of CD23 in detectable amounts. There was a strong correlation between the appearance of soluble CD23 in culture supernatants and the expression of CD23 on the surface of restimulated cells. The level of CD23 release appeared to relate more to the continued cycling of cells than to their differentiation to immunoglobulin secretion. These findings are discussed with particular emphasis on the role of CD23 as an important multi-functional lymphokine in B lymphocyte physiology.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2965643     DOI: 10.1002/eji.1830180305

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  17 in total

Review 1.  Cytokine receptors: structure and signal transduction.

Authors:  B M Foxwell; K Barrett; M Feldmann
Journal:  Clin Exp Immunol       Date:  1992-11       Impact factor: 4.330

2.  CD40 antibodies defining distinct epitopes display qualitative differences in their induction of B-cell differentiation.

Authors:  P Björck; S Paulie
Journal:  Immunology       Date:  1996-02       Impact factor: 7.397

3.  Affinity-purified soluble Fc epsilon RII/CD23 derived from a culture supernatant of an EBV-immortalized B-cell line induced a monophasic fever in rabbits.

Authors:  A A Ghaderi; D R Stanworth
Journal:  Immunology       Date:  1991-08       Impact factor: 7.397

Review 4.  Surface molecules involved in B lymphocyte function.

Authors:  P Möller; A Eichelmann; G Moldenhauer
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

5.  Immunohistochemical demonstration of CD23 expression on lymphocytes in rheumatoid synovitis.

Authors:  E A Hellen; D C Rowlands; T T Hansel; G D Kitas; J Crocker
Journal:  J Clin Pathol       Date:  1991-04       Impact factor: 3.411

6.  Altered production of IgE and IgA induced by IL-4 in peripheral blood mononuclear cells from patients with IgA nephropathy.

Authors:  N Yano; M Endoh; M Miyazaki; F Yamauchi; Y Nomoto; H Sakai
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

7.  Stable transfection of Epstein-Barr virus (EBV) nuclear antigen 2 in lymphoma cells containing the EBV P3HR1 genome induces expression of B-cell activation molecules CD21 and CD23.

Authors:  M Cordier; A Calender; M Billaud; U Zimber; G Rousselet; O Pavlish; J Banchereau; T Tursz; G Bornkamm; G M Lenoir
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

8.  Increased expression of surface IgM but not IgD or IgG on human B cells in response to IL-4.

Authors:  J G Shields; R J Armitage; B N Jamieson; P C Beverley; R E Callard
Journal:  Immunology       Date:  1989-02       Impact factor: 7.397

Review 9.  Cellular signalling mechanisms in B lymphocytes.

Authors:  W Cushley; M M Harnett
Journal:  Biochem J       Date:  1993-06-01       Impact factor: 3.857

10.  Inhibition by glucocorticoid and staurosporine of IL-4-dependent CD23 production in B lymphocytes is reversed on engaging CD40.

Authors:  A Katira; K A Knox; M Finney; R H Michell; M Wakelam; J Gordon
Journal:  Clin Exp Immunol       Date:  1993-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.